GlaxoSmithKline Consumer Healthcare Limited announces results for the second quarter ended September 30 2016
07 November 2016
GlaxoSmithKline Consumer Healthcare Limitedannounces results for the second quarter ended September 30 2016
Highlights for the second quarter ended September 30, 2016
- Profit before tax (PBT) before exceptional items for the quarter up by 1.8%
- YTD September volume market share is at 66.1% (up by 0.7%) & value market share is at 58.2% (up by 0.3%)*
GlaxoSmithKline Consumer Healthcare Limitedtoday declared its financial results for the second quarter ended September 30, 2016. Sales stood at Rs 1,136 crores with an underlying growth of 0.4% and PBT before exceptional items at Rs 288 crores growing by 1.8%. The reported net sales decline of 1.3% got impacted due to one off accounting adjustment sitting in the base and impact of change in accounting standard (IndAS). The PBT declined by 15% on account of one off exceptional income of Rs. 56 Crores sitting in the base year.
The Company’s HFD market share increased by 0.6% during the quarter. The HFD category grew by 0.8% value during Jan – Sept ’16, led by GSKCH +1.2%. Market share for GSK Consumer healthcare has grown in volume at 66.4% (up by 1%) & value at 58.3% (up by 0.5%). The company continues to invest in A&P at 13% of Sales (reported 11% driven by media buying efficiencies).
In a statement, Manoj Kumar, Managing Director, GlaxoSmithKline Consumer Healthcare Limited said, “Despite the subdued demand in the FMCG sector, we have gained share in the HFD category. We continue to improve consumer’s experience with new products like Horlicks Marie, our biggest launch in the foods category.”
“We emphasized on our access strategy with the re-launch of Rs.5 pack of base Horlicks & Boost to ensure that our products are within the easy reach of our larger consumer base. Focus on science, innovation and customer, remains our key differentiator and helps us to stay ahead in the category. Our outlook for the upcoming quarter’s remains positive.” added Kumar.
Product innovations in Q2:
Horlicks Marie: (Launched September’16) The launch in the foods category was Horlicks Marie and it was supported by 360 communication
Women’s Horlicks restage: (Launched August’16) The product was relaunched with a unique combination of Calcium, Vitamin D and Vitamin K2 that helps the bones bind. It was supported by a strong BTL campaign that was activated in outlets across India.
Junior Horlicks:(Launched August’16) Launched a new communication to drive differentiation around brain development and thereby build the need for a specialized health drink in early years. Digital advocacy programs and social media amplification of TVC helped increase engagement, consideration and strengthen benefit perception amongst toddler moms.
*As per Nielsen data
About GlaxoSmithKline Consumer Healthcare Ltd
GSK Consumer Healthcare Ltd is the category leader in Indian health food drinks industry. Our flagship product Horlicks leads the market, while Boost is among the top three health food drink brands that India prefers. Our manufacturing plants are located in Nabha, Rajahmundry and Sonepat. In India we have an engaged workforce of over 4000 employees. GSK also markets and distributes a range of everyday health products such as Eno, Crocin, Iodex and Sensodyne. Our marketing and distribution network comprises over 700 distributors and a direct coverage of 3.3 million retail outlets.
GSK Consumer Healthcare Ltd is an associate of GlaxoSmithKline plc.of U.K, one of world’s largest consumer healthcare companies. We have a heritage that goes back over 160 years. Our purpose is to help more people around the world to do more, feel better and live longer with everyday healthcare products. Our goal is to build a global, growing business - we call a Fast Moving Consumer Healthcare (FMCH) company - dedicated to everyday healthcare with all of the scientific expertise and quality guarantees that demands, working at the speed and with the genuine consumer understanding the modern world expects.
GSK Consumer Healthcare globally owns some of the world’s best loved healthcare brands, successful in over 100 countries. These include Sensodyne, Voltaren, Theraflu, Paradontax, Panadol, Polident, Otrivin, Horlicks and Physiogel.
Rikhil Seth: firstname.lastname@example.org / +91 9811818270
Sakshi Mathur: email@example.com / +91 9999007585
M Sindhu: firstname.lastname@example.org /+91 9899428304
GlaxoSmithKline Consumer Healthcare
Deepa Dey: email@example.com
Kinshuk Gupta: firstname.lastname@example.org